Literature DB >> 14736067

Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia.

Sybille A Miller1, Ann E Hohenhaus, Anne S Hale.   

Abstract

OBJECTIVE: To determine whether blood type, breed, or sex were risk factors for immune-mediated hemolytic anemia (IMHA) in dogs and whether bacteremia was common in dogs with IMHA.
DESIGN: Case-control study. ANIMALS: 33 dogs with IMHA, 1,014 dogs without IMHA for which blood type (dog erythrocyte antigens 1.1, 1.2, 3, 4, 5, and 7) was known, 15,668 dogs without IMHA for which breed was known, and 15,589 dogs without IMHA for which sex was known. PROCEDURE: Blood type, breed, and sex distribution of dogs with IMHA were compared with data for control dogs with Fisher exact tests and by calculating odds ratios (ORs). Results of bacterial culture of blood samples were documented for dogs with IMHA, when available.
RESULTS: Dog erythrocyte antigen 7 was associated with a significant protective effect (OR, 0.1) in Cocker Spaniels with IMHA (n = 10), compared with control dogs. Cocker Spaniels, Bichon Frise, Miniature Pinschers, Rough-coated Collies, and Finnish Spitz had a significantly increased risk of IMHA, as did female dogs (OR, 2.1). Blood samples from 12 dogs with IMHA were submitted for bacterial culture, and none had bacteremia. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that blood type, breed, and sex may play a role in IMHA in dogs.

Entities:  

Mesh:

Year:  2004        PMID: 14736067     DOI: 10.2460/javma.2004.224.232

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Naturally Occurring Adrenocortical Insufficiency--An Epidemiological Study Based on a Swedish-Insured Dog Population of 525,028 Dogs.

Authors:  J M Hanson; K Tengvall; B N Bonnett; Å Hedhammar
Journal:  J Vet Intern Med       Date:  2015-12-18       Impact factor: 3.333

2.  A study on the prevalence of dog erythrocyte antigen 1.1 and detection of canine Babesia by polymerase chain reaction from apparently healthy dogs in a selected rural community in Zimbabwe.

Authors:  Solomon Dhliwayo; Tariro A Makonese; Belinda Whittall; Silvester M Chikerema; Davies M Pfukenyi; Musavenga T Tivapasi
Journal:  J S Afr Vet Assoc       Date:  2016-10-26       Impact factor: 1.474

3.  ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats.

Authors:  Oliver A Garden; Linda Kidd; Angela M Mexas; Yu-Mei Chang; Unity Jeffery; Shauna L Blois; Jonathan E Fogle; Amy L MacNeill; George Lubas; Adam Birkenheuer; Simona Buoncompagni; Julien R S Dandrieux; Antonio Di Loria; Claire L Fellman; Barbara Glanemann; Robert Goggs; Jennifer L Granick; Dana N LeVine; Claire R Sharp; Saralyn Smith-Carr; James W Swann; Balazs Szladovits
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

4.  ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.

Authors:  James W Swann; Oliver A Garden; Claire L Fellman; Barbara Glanemann; Robert Goggs; Dana N LeVine; Andrew J Mackin; Nathaniel T Whitley
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

5.  Analysis of DLA-DQB1 and polymorphisms in CTLA4 in Cocker spaniels affected with immune-mediated haemolytic anaemia.

Authors:  Anna J Threlfall; Alisdair M Boag; Francesca Soutter; Barbara Glanemann; Harriet M Syme; Brian Catchpole
Journal:  Canine Genet Epidemiol       Date:  2015-06-09

6.  Effects of immunosuppressive agents on the hemostatic system in normal dogs.

Authors:  John M Thomason; Todd M Archer; Robert W Wills; Andrew J Mackin
Journal:  J Vet Intern Med       Date:  2018-05-10       Impact factor: 3.333

7.  RNA sequencing of whole blood in dogs with primary immune-mediated hemolytic anemia (IMHA) reveals novel insights into disease pathogenesis.

Authors:  Corie Borchert; Adam Herman; Megan Roth; Aimee C Brooks; Steven G Friedenberg
Journal:  PLoS One       Date:  2020-10-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.